Navigation Links
Opsona Therapeutics Closes EUR18M Funding
Date:2/18/2009

anised monoclonal antibody (OPN-305) to a key toll-like receptor (TLR) target, has demonstrated efficacy in a number of animal models and will start pivotal clinical trials in 2010.

Florent Gros, managing director, Novartis Venture Fund added, "We are delighted to be working with Opsona Therapeutics and the other investors to assist Opsona in progressing the company's highly innovative technology and approaches towards the clinic. The innate immune system represents a new frontier in targeting inflammatory diseases, and the caliber of the investors in this funding round is a demonstration of Opsona's expertise and capabilities in this highly promising field.'

Opsona has also announced the opening of a new facility in Switzerland. The Swiss laboratory will carry out pivotal assay development and biochemical work for new projects and therapeutics recently acquired by Opsona to expand its pipeline of immunomodulators. The expertise that it intends to grow in Switzerland will complement the existing team and activity in Dublin.

Dr Cormac Kilty, Chairman of Opsona and past Chairman of the Irish Bioindustry Association explains "This is major achievement for any biotechnology company in the current economic climate. Opsona's R&D shows that emerging Irish companies can reach international recognition in biotechnology."

Notes to Editors:

About Opsona Therapeutics

Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 with three of Trinity College Dublin's respected Immunologists (Professors Luke O'Neill, Kingston Mills and Dermot Kelleher). The company is specifically interested in drugs which modulate the innate immune system and its signalling, specifically Toll-Like Receptors (TLR). Opsona has a pipeline of therapeutics in advanced pre-clini
'/>"/>

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... IRVINE, Calif. , Feb. 26, 2015 /PRNewswire/ ... of age-defying aesthetic products for skin and hair ... Market Relations as agency of record for investor ... continues to improve our distribution, sales and diversification ... activities to current and prospective shareholders," stated Ali ...
(Date:2/26/2015)... Innovation is more urgent than ever. ... of the world and transforming global markets in ... to health care, disruption is constantly underway. , ... trends shake the foundations of established business models, ... to survive the next wave of mega-change. , ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ... with reovirus are available today on the ... http://www.aacr.org, and on the Oncolytics,website ... scheduled to,be delivered at the AACR Annual ...
... 13 Silence Therapeutics plc,(AIM: SLN) today announces ... development of a range of novel approaches for ... Silence Therapeutics, leading,expertise in the delivery of siRNA ... delivery of siRNA in vivo using its,proprietary AtuPLEX ...
... Today, March 13, 2008 at 11:00 AM ET -, ... reported results for the year and quarter ended,December 31, 2007. ... to $273,000 for the year ended December 31, 2006.,Revenues for ... the same period in 2006., The net loss for ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting 3Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 2Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 4Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 5
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... farm to the insects which blight them mankind has ... species while falling victim to others. In Biological Diversity: ... the subject of biodiversity through the species that humans ... authors selected 18 such organisms and have used them ...
... including several from the Smithsonian Institution, discovered that leaves ... more veins per unit area than leaves ever had ... water available to the leaves, making it possible for ... better plumbing system may also have radically altered water ...
... Techne Corporation,s (NASDAQ: TECH ) consolidated pretax ... increased 9.5% to $45.4 million compared with $41.4 million ... a result of increased sales and foreign exchange transaction ... expenses. For the nine months ended March 31, 2011, ...
Cached Biology News:First rainforests arose when plants solved plumbing problem 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 7
... BacMagic™ DNA Kit provides a positive selection ... recombinant protein expression in insect cells. The ... generating recombinant baculoviruses by eliminating the time-consuming ... is an AcNPV genome with a portion ...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: